Regulatory/inflammatory cellular response discrimination in operational tolerance
Carregando...
Data
Título da Revista
ISSN da Revista
Título de Volume
Editor
Resumo
Background. Antigen-specific cellular response is essential in
immune tolerance. We tested whether antigen-specific cellular
response is differentially modulated in operational tolerance
(OT) in renal transplantation with respect to critical antigenic
challenges in allotransplantation—donor antigens, pathogenic
antigens and self-antigens.
Methods. We analysed the profile of immunoregulatory (REG)
and pro-inflammatory (INFLAMMA) cytokines for the anti gen-specific response directed to these three antigen groups, by
Luminex.
Results. We showed that, in contrast to chronic rejection and
healthy individuals, OT gives rise to an immunoregulatory devi ation in the cellular response to donor human leucocyte antigen
DR isotype peptides, while preserving the pro-inflammatory re sponse to pathogenic peptides. Cellular autoreactivity to the N6
heat shock protein 60 (Hsp60) peptide also showed a REG pro-
file in OT, increasing IL4, IL-5, IL-10 and IL-13.
Conclusions. The REG shift of donor indirect alloreactivity in
OT, with inhibition of interleukin (IL)-1B, IL-8, IL-12, IL-17,
granulocyte colony-stimulating factor, Interferon-c and mono cyte chemoattractant protein-1, indicates that this may be an
important mechanism in OT. In addition, the differential REG
profile of cellular response to the Hsp60 peptide in OT suggests that REG autoimmunity may also play a role in human trans plantation tolerance. Despite cross-reactivity of antigen-specific
T cell responses, a systemic functional antigen-specific discrimi nation takes place in OT.
Descrição
Citação
CARMONA, Priscila et al. Regulatory/inflammatory cellular response discrimination in operational tolerance. Nephrology Dialysis Transplantation, Oxford, v. 34, n. 12, p. 2143-2154, 2019. DOI: 10.1093/ndt/gfz114. Disponível em: https://academic.oup.com/ndt/article/34/12/2143/5529210?login=true. Acesso em: 23 abr. 2025.